ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia (CME-LEM1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01909154
Recruitment Status : Completed
First Posted : July 26, 2013
Last Update Posted : June 18, 2015
Sponsor:
Information provided by (Responsible Party):
Jesús Vaquero Crespo, M.D., Puerta de Hierro University Hospital

July 7, 2013
July 26, 2013
June 18, 2015
March 2013
April 2014   (Final data collection date for primary outcome measure)
Safety [ Time Frame: Up to 12 months ]

Clinical evaluation of possible adverse effects is performed daily at the first week after the first administration of stem cells and weekly until the 6 months follow-up visit and then at month 9 and 12.

  • During the first stem cells administration (during surgery): Changes in vital signs (ECG, Blood Pressure (BP), Heart Rate (HR) were evaluated
  • During the second stem cells administration: Changes in vital signs (BP, HR), headache and meningeal irritation were evaluated
  • During the first weeks, after the first and the second administrations, the possibility of meningeal irritation, headache and infectious complications were considerate.
Appearance of adverse effects [ Time Frame: Up to 12 months ]

The principal variable will be the appearance of adverse effects during administration and during the follow up period:

On a daily Bases: The first week after first administration of CME. Weekly: Until the second administration of CME After second administration of CME it will be done a weekly clinical assessment and during months 9 and 12 of the follow-up period.

Complete list of historical versions of study NCT01909154 on ClinicalTrials.gov Archive Site
Efficacy [ Time Frame: sensitivity recovery during Follow-up period: 3, 6, 9 and 12 months and the baseline visit. ]

Sensitivity recovery, changes in the level of chronic pain, neurophysiological parameters improvement, and changes in the spinal cord morphology on neuroimaging studies.

Sensitive recovery: Follow-up period: 3, 6, 9 and 12 months and the baseline visit.

  • Sensitivity recovery [ Time Frame: sensitivity recovery during Follow-up period: 3, 6, 9 and 12 months and the baseline visit. ]

    Sensitivity recovery, changes in the level of chronic pain, neurophysiological parameters improvement, and changes in the spinal cord morphology on neuroimaging studies.

    Sensitive recovery: Follow-up period: 3, 6, 9 and 12 months and the baseline visit.

  • Motor recovery [ Time Frame: Motor recovery during administration and during the follow up period: Follow-up period: 3,6,9, and 12 months and baseline visit. ]

    Motor recovery, changes in the level of chronic pain, neurophysiological parameters improvement, and changes in the spinal cord morphology on neuroimaging studies.

    Motor recovery: Follow-up period: 3,6,9, and 12 months and baseline visit.

Not Provided
Not Provided
 
Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia
Phase I Pilot Study to Evaluate the Security of Local Administration of Autologous Stem Cells Obtained From the Bone Marrow Stroma, in Traumatic Injuries of the Spinal Cord
The purpose of this study is to confirm the security, and detect the effect of the local administration in damaged nervous tissue, of autologous bone marrow stromal cells.
It is a clinical trial phase I, single center, non-randomized, uncontrolled, open prospective follow-up of a cohort of patients with chronic spinal cord injury (SCI) who were treated with autologous stromal cells of the bone marrow administrated locally (subarachnoid and intramedullar) by intrathecal microinjection and three months later, by lumbar subarachnoid administration. The minimum follow-up duration for each patient is 12 months after the first administration, or until death, if it occurs it before.
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Spinal Cord Injury
Biological: Mesenchymal stromal cell therapy
Other Name: BMMSCs= Bone Marrow Mesenchymal Stem Cells
Experimental: Mesenchymal stromal cell therapy
Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later
Intervention: Biological: Mesenchymal stromal cell therapy
Geffner LF, Santacruz P, Izurieta M, Flor L, Maldonado B, Auad AH, Montenegro X, Gonzalez R, Silva F. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant. 2008;17(12):1277-93.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
Same as current
March 2015
April 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female with ages between 18 years and 60 years with of age or older functional sequelae chronically established by traumatic injury of the spinal cord (spinal segments between the vertebral bodies C6 and L1) and considered irreversible (not respond to any other treatment). In this study, the lesion is considered chronically established, when there are no signs of functional recovery after a minimum follow-up period of 6 months after the spinal cord injury. The upper age limit is justified by the low potential of in vitro expansion of bone marrow stromal cells over 60 years.
  • Complete paraplegia, with loss of motor and sensory function below the lesion (grade A in the American Spinal Injury Association Impairment (ASIA) Scale .
  • Spinal injury MRI morphologically visible, and without images that suggest spinal cord transection, with separation of the both ends of the spinal cord.
  • Tracking evolutionary possibility after treatment protocol and to comply physiotherapy maintained throughout the follow up period.
  • Written informed Consent according to good clinical practice (GCP) and local regulations, obtained before any study procedure.
  • Hematological parameters and creatinine, serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) in normal range according to laboratory standards, are accepted, however, small non-significant deviations according to the investigator.

Exclusion criteria:

  • Pregnancy and lactation
  • Systemic disease represents an added risk to treatment
  • Patients with questions about their possible cooperation in rehabilitation-physiotherapy treatments later, or negative report psychological assessment prior.
  • Neuroimaging data showing spinal cord section with separation of the terminal portion of the spinal cord
  • Current neoplastic disease diagnosed or treated in the previous five years
  • Patients treated with hematopoietic growth factors or requiring stable anticoagulation
  • Added neurodegenerative disease
  • History of substance abuse, psychiatric illness or allergy to protein products used in the process of cell expansion
  • HIV positive serology and syphilis
  • Hepatitis B or Hepatitis C active According to the investigator's opinion if there are findings on physical examination, abnormal clinical test results or other medica relevant entries, social or psychosocial factors which might influence negatively the study.
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT01909154
CME-LEM1
2010-023285-46 ( EudraCT Number )
No
Not Provided
Not Provided
Jesús Vaquero Crespo, M.D., Puerta de Hierro University Hospital
Puerta de Hierro University Hospital
Not Provided
Principal Investigator: Jesus JV Vaquero Crespo, Dr. Hospital Universitario Puerta de Hierro-Majadahonda
Puerta de Hierro University Hospital
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP